LinkedIn-button

Services

Vaccine
development
service

The bridge between discovery
and pilot-scale GMP biomanufacturing.
Intravacc offers a one-stop shop
for independent vaccine development,
from discovery to pilot production
to clinical studies.

LEARN MORE
LinkedIn-button

Discover
Intravacc

Intravacc, located at Utrecht Science Park Bilthoven in the Netherlands, is a leading global contract development and manufacturing organization of innovative vaccines against infectious diseases. With over 100 years of experience in vaccine development and optimization, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world.

LEARN MOREANNUAL REPORT 2021
LinkedIn-button

Latest News

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant Bilthoven, the Netherlands / Munich, Germany, 6 July 2022 – Intravacc, a world leading contract development and manufacturing organization (CDMO) of preventive and therapeutic vaccines and the…

  • Total amount of €2.5 million for amyotrophic lateral sclerosis (ALS) vaccine development
  • ALS vaccine is targeting the most common genetic ALS variant
  • 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene
Read more

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors

Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors Bilthoven, the Netherlands, 5 July 2022 – Intravacc B.V., a world leader in translational research and development of preventive and therapeutic vaccines, today announced…

  • Publication annual report 2021
  • Appointment of a Chief Business Officer
  • Appointment of a Director vaccine process development
  • Chief Financial Officer joins the Board of Directors
Read more

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3

Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3 – an OMV based whooping cough vaccine Bilthoven, the Netherlands, 2 May 2022 – Intravacc B.V., a world leader in translational research and development of preventive…

  • Avacc 3 has significant advantages over existing whooping cough vaccines
  • Second major OMV platform licensing agreement with pharmaceutical company
  • Over 24 million cases of whooping cough per year world-wide
Read more
LinkedIn-button

Career

Join our team!

Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.

YOUR CAREER?

Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.